Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Het Nationale Longkanker Symposium 2023: de belangrijkste ontwikkelingen
feb 2023